|
Video: What is a Stock Split?
|
|
Mirati Therapeutics is a clinical-stage oncology company developing therapeutics to address the genetic and immunological promoters of cancer. Co.'s product candidates include: Adagrasib, an investigational, selective, specific, potent and orally available KRAS G12C inhibitor in clinical development as a monotherapy and in combination with other agents; MRTX1133, an investigational, selective, specific and potent KRAS G12D inhibitor in preclinical development; Sitravatinib, an investigational spectrum-selective kinase inhibitor; and MRTX1719, an internally discovered investigational synthetic lethal PRMT5 inhibitor to target the PRMT5/methylthioadensoine complex in preclinical development. According to our MRTX stock split history records, MRTX has had 0 splits. | |
|
MRTX (MRTX) has 0 splits in our MRTX stock split history database.
Looking at the MRTX stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into MRTX shares, starting with a $10,000 purchase of MRTX, presented on a split-history-adjusted basis factoring in the complete MRTX stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/25/2014 |
|
End date: |
01/23/2024 |
|
Start price/share: |
$18.91 |
|
End price/share: |
$58.70 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
210.42% |
|
Average Annual Total Return: |
12.32% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$31,054.85 |
|
Years: |
9.75 |
|
|
|
|
|